These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators. Wu J; Jordan M; Waxman DJ BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027 [TBL] [Abstract][Full Text] [Related]
3. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model. Wu J; Waxman DJ Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038 [TBL] [Abstract][Full Text] [Related]
4. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. Doloff JC; Chen CS; Waxman DJ Mol Cancer; 2014 Jun; 13():158. PubMed ID: 24965046 [TBL] [Abstract][Full Text] [Related]
5. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model. Jordan M; Waxman DJ Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275 [TBL] [Abstract][Full Text] [Related]
6. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models. Du B; Waxman DJ Cancer Lett; 2020 Feb; 470():170-180. PubMed ID: 31765733 [TBL] [Abstract][Full Text] [Related]
7. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Chen CS; Doloff JC; Waxman DJ Neoplasia; 2014 Jan; 16(1):84-96. PubMed ID: 24563621 [TBL] [Abstract][Full Text] [Related]
8. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Doloff JC; Waxman DJ Cancer Res; 2012 Mar; 72(5):1103-15. PubMed ID: 22237627 [TBL] [Abstract][Full Text] [Related]
9. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8 Wu J; Waxman DJ Oncoimmunology; 2015 Apr; 4(4):e1005521. PubMed ID: 26137402 [TBL] [Abstract][Full Text] [Related]
10. Delicate Balances in Cancer Chemotherapy: Modeling Immune Recruitment and Emergence of Systemic Drug Resistance. Tran AP; Ali Al-Radhawi M; Kareva I; Wu J; Waxman DJ; Sontag ED Front Immunol; 2020; 11():1376. PubMed ID: 32695118 [TBL] [Abstract][Full Text] [Related]
11. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide. Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014 [TBL] [Abstract][Full Text] [Related]
12. Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine breast cancer. Vergato C; Doshi KA; Roblyer D; Waxman DJ Cancer Res Commun; 2022 Apr; 2(4):246-257. PubMed ID: 36187936 [TBL] [Abstract][Full Text] [Related]
13. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Ma J; Waxman DJ Mol Cancer Ther; 2008 Jan; 7(1):79-89. PubMed ID: 18202011 [TBL] [Abstract][Full Text] [Related]
14. Repeated tumor oximetry to identify therapeutic window during metronomic cyclophosphamide treatment of 9L gliomas. Mupparaju S; Hou H; Lariviere JP; Swartz H; Jounaidi Y; Khan N Oncol Rep; 2011 Jul; 26(1):281-6. PubMed ID: 21503586 [TBL] [Abstract][Full Text] [Related]
15. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma. Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122 [TBL] [Abstract][Full Text] [Related]
16. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model. Shiraga E; Barichello JM; Ishida T; Kiwada H Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369 [TBL] [Abstract][Full Text] [Related]
17. Histone acetyltransferase inhibitor II induces apoptosis in glioma cell lines via the p53 signaling pathway. Xu LX; Li ZH; Tao YF; Li RH; Fang F; Zhao H; Li G; Li YH; Wang J; Feng X; Pan J J Exp Clin Cancer Res; 2014 Dec; 33(1):108. PubMed ID: 25523932 [TBL] [Abstract][Full Text] [Related]
18. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065 [TBL] [Abstract][Full Text] [Related]
19. Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. Denies S; Cicchelero L; Van Audenhove I; Sanders NN J Control Release; 2014 Aug; 187():175-82. PubMed ID: 24887014 [TBL] [Abstract][Full Text] [Related]